TANDEM DIABETES CARE INC (TNDM) FY2025 10-K Annual Report
TANDEM DIABETES CARE INC (TNDM) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
TANDEM DIABETES CARE INC FY2025 10-K Analysis
Business Overview
- • Core business model: Design, development, and commercialization of advanced insulin delivery and diabetes technology with AID systems featuring Control-IQ+ hybrid closed-loop technology
- • New product emphasis: Expanded commercial availability of Tandem Mobi with Android control (2025) and Control-IQ+ algorithm cleared for type 2 diabetes (18+ years) in 2025
- • Strategic shift: Beginning direct sales, training, and support in UK, Austria, Switzerland (2026), transitioning from distributor model internationally
- • Quantitative highlight: Serving nearly 500,000 people in 25+ countries with estimated addressable market expansion to type 2 insulin-dependent diabetes patients beginning 2025
- • Noteworthy fact: Launch of next-generation Mobi patch pump and extended-wear infusion set pipeline targeting fully closed-loop technology and device miniaturization
Management Discussion & Analysis
- • Revenue $1.015B in 2025, up 8% YoY from $940.2M in 2024; U.S. sales $706.9M (+5%), international $307.8M (+15%)
- • Gross margin 54% in 2025 vs 52% in 2024; operating loss $(187.3M) vs $(99.1M) reflecting higher operating expenses ($733.3M vs $588.7M)
- • Best segment: International sales growth +$40.3M to $307.8M driven by volumes, price, and FX; worst: U.S. pumps with slower shipment growth (~81K to 86K units)
- • Cash flow: Operating cash used $(9.7M) vs provided $24.2M; investing cash provided $72.9M due to short-term investment maturities; financing used $43.4M mainly for debt repayment
- • Outlook: Transition to pharmacy benefit "pay as you go" reimbursement in 2026 may reduce upfront pump sales, increase supply sales; regulatory, reimbursement, and macroeconomic risks noted
Risk Factors
- • Cybersecurity risk managed by dedicated Incident Management Team led by VP, Cybersecurity with 20+ years industry experience
- • Escalation protocols include disclosure committee and Cybersecurity and Data Privacy Oversight Committee to address significant incidents
- • Regular detailed cybersecurity threat and mitigation reports reviewed by Cybersecurity and Data Privacy Oversight Committee and full Board
- • Integration of cybersecurity risk considerations into overall risk management and budgeting controlled by VP, Cybersecurity
- • Cross-departmental leadership on cybersecurity includes Chief HR Officer, VP Privacy, legal, finance, and business unit personnel
TANDEM DIABETES CARE INC FY2025 Key Financial MetricsXBRL
Revenue
$1.0B
▲ +7.9% YoY
Net Income
-$205M
▼ -113.2% YoY
Gross Margin
53.8%
▲ +174bp YoY
Operating Margin
-18.5%
▼ -791bp YoY
Net Margin
-20.2%
▼ -996bp YoY
ROE
-131.9%
▼ -9543bp YoY
Total Assets
$881M
▼ -8.9% YoY
EPS (Diluted)
$-3.04
▼ -106.8% YoY
Operating Cash Flow
-$10M
▼ -140.1% YoY
Source: XBRL data from TANDEM DIABETES CARE INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on TANDEM DIABETES CARE INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.